May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
NAT–2. Report #1: High HDL and Low PUFAs Levels in Exudative AMD Patients
Author Affiliations & Notes
  • E.H. Souied
    Creteil Eye Clinic, Creteil Eye Clinic Univ Hospital, Creteil, France
  • N. Leveziel
    Creteil Eye Clinic, Creteil Eye Clinic Univ Hospital, Creteil, France
  • C. Delcourt
    Inserm U593, Université Victor Segalen / Bordeaux, France
  • B. Paccou
    Creteil Eye Clinic, Creteil Eye Clinic Univ Hospital, Creteil, France
  • I. Carrière
    Inserm E0361, Montpellier, France
  • M. Lablache–Combier
    Bausch & Lomb, Paris, France
  • C. Allaire
    Bausch & Lomb, Paris, France
  • G. Coscas
    Creteil Eye Clinic, Creteil Eye Clinic Univ Hospital, Creteil, France
  • G. Soubrane
    Creteil Eye Clinic, Creteil Eye Clinic Univ Hospital, Creteil, France
  • P. Benlian
    Biochemistery, Hopital Saint Antoine, Paris, France
  • Footnotes
    Commercial Relationships  E.H. Souied, Bausch & Lomb, C; Bausch & Lomb, R; N. Leveziel, None; C. Delcourt, Bausch & Lomb, C; B. Paccou, None; I. Carrière, None; M. Lablache–Combier, Bausch & Lomb, E; C. Allaire, Bausch & Lomb, E; G. Coscas, None; G. Soubrane, Bausch & Lomb, R; P. Benlian, Bausch & Lomb, R.
  • Footnotes
    Support  Bausch & Lomb
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2181. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E.H. Souied, N. Leveziel, C. Delcourt, B. Paccou, I. Carrière, M. Lablache–Combier, C. Allaire, G. Coscas, G. Soubrane, P. Benlian; NAT–2. Report #1: High HDL and Low PUFAs Levels in Exudative AMD Patients . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2181.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : NAT–2 is a double–masked, randomised, parallel, comparative study of oral supplementation with DHA (Docosahexaenoic acid) versus placebo in the prevention of exudative age related macular degeneration. Here, our purpose is to compare circulating lipids profile in NAT–2 patients at baseline, with that found in French control individuals.

Methods: : Patients from the NAT–2 study were included if they had exudative AMD in one eye and any type of drusen in the study eye. Twelve–hour fasting serum cholesterol, triglycerides, HDL, saturated fatty acids, mono–unsaturated (MUFAs), poly–unsaturated fatty acids (PUFAs) extracted from serum lipids were measured in 298 patients from the NAT2 study at baseline. The control group consisted of 2030 French individuals without any drusen or macular lesion. Comparisons between NAT2 participants and the control group were adjusted on age and gender, using analysis of covariance.

Results: : Median age was 76.0 years at entry (versus 69.4 in the control group p < 0.0001). Gender distribution was 36% males in the NAT–2 population and 43% males in the control group (p=0.02). Serum total cholesterol was comparable in both groups. HDL level mean (95%CI) was particularly elevated in the NAT–2 population: 1.74 (1.70; 1.78) mmol/l (versus 1.37 (1.35; 1.39) in controls; p<0.0001). Mean MUFAs level was also elevated in the NAT–2 population: 24.9% (24.4; 25.4) (versus 20.4% (20.2; 20.6) in controls; p<0.0001). Mean Omega–6, Omega–3 and DHA levels were lower in the NAT–2 population: respectively 32.4% (31.8; 33.0), 2.34% (2.21; 2.48), 1.28% (1.21; 1.36) (versus respectively 37.2% (37.0; 37.4), 3.06% (3.0; 3.12), 1.89% (1.85; 1.93) in controls; p<0.0001).

Conclusions: : NAT–2 study revealed high HDL levels and low PUFAs levels, particularly low DHA levels, in exudative AMD patients. These findings support the hypothesis for the need of a DHA supplementation in AMD patients.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • lipids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×